Obio Technology and Renyuan Biotechnology Form Strategic Partnership for EPC Cell Project

Shanghai Obio Technology (Group) Corp., Ltd. and Renyuan Biotechnology (Shenzhen) Co., Ltd. have announced a strategic partnership to advance the EPC cell project, focusing on preclinical CMC pharmaceutical research and the complete IND application process.

The collaboration aims to accelerate the clinical translation of innovative cell therapies while establishing standardized development protocols. Both companies will work together to address unmet needs in clinical treatment.

This partnership represents a significant step in advancing cell therapy development in China, combining Obio's expertise in biotechnology with Renyuan's capabilities in pharmaceutical research and development.